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Tumour angiogenesis has become an important target for antitumour therapy, with most current therapies aimed at blocking the
VEGF pathway. However, not all tumours are responsive to VEGF blockers, and some tumours that are responsive initially may
become resistant during the course of treatment, thus there is a need to explore other angiogenesis signalling pathways. Recently, the
Delta-Notch pathway, and particularly the ligand Delta-like 4 (Dll4), was identified as a new target in tumour angiogenesis. An
important feature in angiogenesis is the manifold ways in which the VEGF and Delta-Notch pathways interact. The emerging picture is
that the VEGF pathway acts as a potent upstream activating stimulus for angiogenesis, whereas Delta-Notch helps to guide cell fate
decisions that appropriately shape the activation. Here we review the two signalling pathways and what is currently known about the
ways in which they interact during tumour angiogenesis.
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Solid tumours require the growth of new blood vessels (angio-
genesis) to grow (Folkman, 2002). Tumour angiogenesis utilises
at least some of the angiogenic signalling pathways that are
required during vascular development. Over the past 10 years,
these pathways have been recognised as important targets for
antitumour therapy, and a number of different approaches to
block angiogenic signalling pathways, and thus block tumour
growth, have been developed.
At the present time, blocking the VEGF pathway is the best-
validated approach to blocking tumour angiogenesis. Studies from
a number of years ago showed that the VEGF pathway is central
and absolutely essential for early stages of developmental
angiogenesis; these findings helped drive the development of
VEGF inhibitors for clinical use (Ferrara, 1999). However, unlike
developmental angiogenesis, not all tumours are responsive to
VEGF blockers, and some tumours that are responsive initially
may become resistant during the course of treatment. Thus, there
is a need to explore other angiogenesis signalling pathways as
therapeutic targets, including those that interact with the VEGF
pathway.
One such pathway is Delta/Jagged-Notch signalling system,
which is generally involved in cell fate decisions. One particular
ligand, Dll4, was recently identified as a potentially important new
target in tumour angiogenesis. Other members of this pathway,
including Notch receptors, are also required for developmental
angiogenesis. The emerging picture is that the VEGF pathway acts
as a potent upstream activating stimulus for angiogenesis, whereas
Delta-Notch helps to shape that activation appropriately. An
important feature of angiogenesis is the manifold ways in which
the VEGF and Delta-Notch pathways interact.
In this review, we briefly summarise the components and
features of the VEGF and Delta-Notch pathways, including their
roles in developmental and tumour angiogenesis. Then we
summarise in more detail what is currently known about the ways
in which these pathways interact in the vasculature. A deeper
understanding of these interactions should lead to better use of
agents that block the Dll4-Notch pathway, alone and in combina-
tion with currently used inhibitors of the VEGF pathway.
THE VEGF PATHWAY
Molecular components, general features and functions
The VEGF system has been conserved from zebrafish to man as a
signalling pathway that is essential and rather specific to the
vascular and haematopoietic systems. In mammals, the system
comprises five secreted ligands (VEGF-A, VEGF-B, VEGF-C,
VEGF-D and PlGF) and three primary receptors (VEGF-R1,
VEGF-R2, VEGF-R3). In general, the ligands are expressed rather
broadly and display multiple splice isoforms of varying size and
degree of interaction with the extracellular matrix. An important
point is that the expression of VEGF-A is induced by hypoxia,
which is a common feature of rapidly growing solid tumours, and
constitutes a key signal from a tissue calling for more blood vessels
and/or increased vascular function. In contrast to the ligands, the
receptors show much more restricted cell-type expression. VEGF-
R1 and VEGF-R2 are prominently expressed by vascular endo-
thelial cells in addition to expression by selected other cell types.
VEGF-R3 is prominently expressed in lymphatic endothelial cells,
although it can also be expressed on activated blood endothelial
cells (Tammela et al, 2005). The ligands show discrete binding to
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and VEGF-R2, whereas PlGF interacts strictly with VEGF-R1.
Additional components of the system include the cell-surface
proteins, neuropilin-1 and -2, which can serve as coreceptors on
endothelial cells for larger isoforms of VEGF-A and VEGF-C. The
VEGF receptors are tyrosine kinases that autophosphorylate upon
dimerisation by ligand, which in turn activates various down-
stream signalling pathways. Signals from VEGF receptors drive
diverse cellular effects in endothelial cells, including migration,
proliferation, cell survival and the expression of downstream
genes.
Genetic deletion in mice and knockdown in zebrafish
Genetic targeting studies in mice have emphasised the essential
nature of the VEGF pathway for the development of the blood and
lymphatic vascular systems. Genetic deletion of VEGF-A or its
primary signalling receptor VEGF-R2 results in early embryonic
lethality (approximately embryonic day E9), associated with a
near-complete block of haematopoietic and vascular development.
Somewhat analogously, deletion of VEGF-C results in a severe
block in the development of the lymphatic system. Deletion of the
main receptor for VEGF-C, VEGF-R3, results in embryonic
lethality associated with blood vascular defects; however, this
receptor becomes essential for the development of the lymphatic
system slightly later in development (Tammela et al, 2005).
Deletion of VEGF-R1 also results in embryonic lethality, although
in this case, the defect is an overabundance of blood vessels.
Deletion of other VEGF ligands (PlGF, VEGF-B, VEGF-D) is not
lethal and is associated with much more subtle phenotypes. Studies
in zebrafish also reveal essential upstream roles for the VEGF
system: high-dose morpholino knockdown of VEGF-A in early
zebrafish embryos (day 2) results in a near-total absence of vascu-
lature (similar to results in mice), whereas lower dose
VEGF-A knockdown results in severe disruption of the dorsal
aorta and intersegmental arteries (Nasevicius et al, 2000; Lawson
et al, 2002).
Blockade of the VEGF pathway in tumours
The VEGF pathway was identified as a target for antitumour
therapy more than 15 years ago, and early studies showed that
blocking the VEGF-A ligand with a monoclonal antibody could
result in strong suppression of tumour growth (Ferrara, 1999).
Since these initial studies, many different approaches have been
taken to block the VEGF pathways, focusing on VEGF-A ligand and
VEGF-R2 receptor (Duda et al, 2007). Various preclinical studies
have shown that successful blockade of the pathway in tumour-
bearing mice results in vessel pruning and reduction of angiogenic
sprouting, which produce a ‘normalisation’ of the aberrant tumour
vessels (Duda et al, 2007). The reduced tumour angiogenesis leads
to reduced tumour growth in a broad variety of tumour types.
These preclinical results have been validated by successful phase 3
clinical trials of anti-VEGF agents in several types of cancers,
including colorectal, renal cell carcinoma and breast cancer. Studies
in numerous cancer indications are currently ongoing.
THE DELTA/JAGGED-NOTCH PATHWAY
Molecular components, general features and functions
Notch is a fundamental signalling pathway in many mammalian
cell types undergoing differentiation, primarily acting to regulate
cell fate determination. Delta-Notch signalling is a form of cell–
cell communication, helping a group of similar cells to integrate
contextual information and steer down separate pathways of
differentiation. One mechanism, referred to as lateral inhibition,
involves presentation of a Notch ligand (Delta or Jagged) to an
adjacent Notch receptor cell, resulting in activation of the Notch
pathway in one cell and suppression in the adjacent cells. The end
result locks the cells into distinct cellular fates; one promoted by
Notch signal activation and the other dependent on lack of
Notch signalling. Notch receptors are distinct in that they operate
both on the cell surface to bind ligand and within the nucleus as
transcriptional modulators (Mumm and Kopan, 2000). The path-
way in mammals is comprised of a conserved family of four
transmembrane receptors (Notch1–4). In the vasculature, Notch1
and Notch4 function in developing endothelium, whereas Notch3
is critical for smooth muscle cell differentiation. Mammals utilise
five membrane-bound Notch ligands (Delta-like 1, 3, 4, Jagged1
and -2). Those ligands implicated in the process of angiogenesis
include Delta-like 1 (Dll1), Delta-like 4 (Dll4) and Jagged1.
Receptor–ligand interactions between adjacent cells first trigger
the metalloproteinase ADAM (a disintegrin and metalloproteinase)
to cleave the Notch extracellular region and then trigger
g-secretase-mediated generation of the Notch intracellular domain
(NICD). Subsequently, NICD translocates to the nucleus, where it
interacts with the CSL (RBPJ) transcription factor to induce
multiple downstream targets, including a family of basic helix-
loop-helix proteins, the Hes and Hey genes (Mumm and Kopan,
2000).
Genetic deletion in mice and knockdown in zebrafish
Mice with targeted deletions of Notch family genes exhibit diverse
vascular defects, mostly affecting the process of vascular remodel-
ling and arterial specification. Notch1, Dll4 and CSL mutations
result in the most severe vascular disruptions. The Notch1 null
mice die due to profound defects of angiogenic vascular
remodelling, shown most obviously as a failure of proper
formation of the major arteries. The mice form a primary vascular
plexus, indicating that Notch signals are not required for
vasculogenesis and early angiogenesis; however, this plexus fails
to remodel into an organised network of larger and smaller vessels
(Krebs et al, 2000). Mice lacking the Notch4 gene develop
normally; however, Notch1/Notch4 double mutants show more
severe vascular defects than mice lacking only Notch1, suggesting
that Notch1 and Notch4 have partially redundant functions (Krebs
et al, 2000). Proper vascular development requires appropriate
Notch activity, as mice with an activated allele of Notch4 (Notch4/
int3) die in utero and display severe vascular anomalies,
reminiscent of those seen in Notch1 null mice (Uyttendaele et al,
2001). Similarly, targeted endothelial expression of INT3 produces
reversible arteriovenous defects in adult mice (Carlson et al, 2005).
Jagged1 deletion also results in lethality due to haemorrhage and
failure in angiogenic remodelling (Xue et al, 1999). In support of
its role as the primary endothelial cell Notch ligand, heterozygous
deletion of Dll4 is lethal. Vascular defects in Dll4 mutants include
arteriovenous malformations, a lack of vascular remodelling and
collapse or incomplete formation of the major arteries (Duarte
et al, 2004; Gale et al, 2004; Krebs et al, 2004). In rare-surviving
Dll4 heterozygous mice, defects were also noted in sprouting
angiogenesis in the neonatal retinal vessels (Lobov et al, 2007;
Suchting et al, 2007); these defects are understood in terms of a
failure for local cell fate decisions in the leading front of angiogenic
vessels (see below). In zebrafish, Delta-Notch signalling has been
shown to be important for the differentiation of arterial endothelial
cells and proper formation of the major arteries (Lawson et al,
2001). In addition, Notch signalling is also required for proper
control of angiogenic sprouting of, for example, the intersomitic
vessels (Leslie et al, 2007; Siekmann and Lawson, 2007).
Blockade of Dll4 in tumours
As could be expected from its role in developmental angiogenesis,
the Delta-Notch pathway is also important in tumour angiogenesis.
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components in tumour vessels, most notably Dll4. Studies of
tumours in mice and humans have shown that Dll4 is strongly
expressed in tumour blood vessels compared to adjacent normal
vessels. For example, in human tumours, Dll4 expression was
localised to the blood vessels of clear-cell renal tumours (Mailhos
et al, 2001) and was at nine-fold higher levels than in normal
kidney tissue (Patel et al, 2005). In keeping with the studies
described above, expression of Dll4 in tumour vessels appears to
be directly regulated by VEGF. For example, blockade of VEGF in
tumour-bearing mice results in a rapid and profound reduction of
Dll4 expression by the tumour blood vessels (Noguera-Troise et al,
2006). Conversely, the levels of Dll4 expression in tumours
correlate with the levels of VEGF expression (Patel et al, 2006).
Thus, the high levels of Dll4 expression on tumour vessels may be
a result of relatively high levels of VEGF signalling in these vessels
compared to most normal vessels.
The striking pattern of Dll4 expression in tumour vessels
prompted several groups to target Dll4-Notch activity and
provided insight into a role for Dll4-Notch in regulating VEGF-
induced vascular sprouting. Local or systemic treatment of mice
with Dll4-Notch inhibitors caused overgrowth of a non-functional
tumour vasculature. However, strikingly, blockade of Dll4-Notch
resulted in a growth inhibition in a variety of established human
and rodent tumour models (Noguera-Troise et al, 2006; Ridgway
et al, 2006; Scehnet et al, 2007). The reduced growth was associated
with an increase in tumour vessel density and increased vessel
sprouts with numerous interconnecting branches. Even though the
tumours were smaller due to Dll4 blockade, tumours were more
hypoxic, apparently containing non-functional vessels (‘abnorma-
lisation’ – Thurston et al, 2007).
Other Notch ligands may also influence tumour angiogenesis;
for example, one study suggests an angiogenic role for Jagged1 in
head and neck tumours (Zeng et al, 2005). A similar conclusion
was reached in a study of a novel Notch inhibitor, the Notch1
decoy, which has the ability to block Notch signalling via several
different Notch ligands, including both Dll4 and Jagged1. The
Notch1 decoy was shown to block angiogenesis in both a VEGF-
driven dermal angiogenesis model and a xenograft model of
mammary tumour growth (Funahashi et al, 2008). It remains to be
established which ligands are most critical for the antiangiogenic
effect of the Notch1 decoy.
INTERACTIONS OF VEGF AND DELTA-NOTCH
PATHWAYS
Genetic evidence for interaction between VEGF and
Delta-Notch pathways
An initial appreciation of the relationship between the VEGF
pathway and the Delta-Notch pathway came from studies of
vascular development in zebrafish. Several studies have shown that
loss of Notch signalling, for example with morpholino knockdown
of Notch receptors or in mutants of the downstream gene gridlock,
leads to defective development of the arterial vessels (Zhong et al,
2001). Subsequently, VEGF was shown to act upstream of Notch in
determining arterial cell fate in vascular development (Lawson
et al, 2002). By analogy to the studies of VEGF activity in cultured
endothelial cells, it is possible that VEGF signalling leads to
increased Dll4 and Notch expression, in turn leading to productive
Notch signalling and thus arterial specification characterised by
expression of a defined set of arterial genes. However, it is not clear
whether a VEGF signal in isolation can induce de novo expression
of Notch components (Lawson et al, 2002). More work will be
needed to fully define the biochemical link between the VEGF
pathway and the Delta-Notch pathway in this setting (Siekmann
et al, 2008).
VEGF increases Dll4 expression
Studies in several systems, discussed here, establish that VEGF
regulates the expression of Notch signalling components. Studies
with cultured endothelial cells reveal several ways in which the
VEGF and Dll4-Notch pathways interact. Importantly, VEGF
increases Dll4 expression. Treatment of cultured endothelial cells
with VEGF results in increased expression of Dll4 mRNA and
protein (Patel et al, 2005; Hainaud et al, 2006; Ridgway et al, 2006).
Vascular endothelial growth factor is a classic hypoxia response
gene; thus the induction of Dll4 can occur indirectly in situations
of hypoxia, via induction of VEGF. In addition, Dll4 expression by
endothelial cells may be directly upregulated by hypoxia, possibly
via Hif1-a and hypoxia response elements in the Dll4 promoter
(Patel et al, 2005; Diez et al, 2007).
The expression of Dll4 is also increased by VEGF in vivo. Dll4 is
strongly expressed by endothelial cells of sprouting angiogenic
vessels, which are commonly responding to VEGF signals. For
example, in the developing murine retina, a VEGF gradient
emanating from the avascular regions of the retina is essential for
the sprouting angiogenesis. These growing vessels, and in
particular the ‘tip cells’, are associated with strong expression of
Dll4 (Hellstrom et al, 2007; Lobov et al, 2007). Blocking VEGF, by
intravitreal injection of soluble VEGF receptors, results in
decreased sprouting and decreased expression of Dll4 on the
retinal vessels (Suchting et al, 2007). Conversely, intravitreal
injection of VEGF protein increased expression of Dll4 in the
retina (Lobov et al, 2007). Furthermore, in an oxygen-induced
model of retinal angiogenesis (OIR), Dll4 expression is also
increased on the newly forming retinal vessels (Lobov et al, 2007).
Again, specific blockade of VEGF blocks the increased expression
of Dll4 on the newly forming retinal vessels in the OIR model. It is
noteworthy that blocking VEGF in this model does not reduce
expression of Dll4 on arteries, indicating that other signals can also
induce expression of Dll4.
Similar associations between VEGF signalling, growing vessels
and Dll4 expression have been found in tumour vessels (Mailhos
et al, 2001; Patel et al, 2005; Noguera-Troise et al, 2006). As
described above, VEGF drives a key pathway for tumour
angiogenesis in many models, and ongoing VEGF signalling is
often required for sprouting angiogenesis in tumours. Increased
expression of Dll4 in tumour vessels has been reported in several
mouse tumour models (Mailhos et al, 2001; Noguera-Troise et al,
2006) and in human tumours (Patel et al, 2005). For example, Dll4
expression was found to be particularly strong on the growing
front of vessels as tumours become vascularised (Noguera-Troise
et al, 2006). Conversely, blockade of VEGF in tumours resulted in a
rapid decrease of Dll4 expression in tumour vessels (Noguera-
Troise et al, 2006), showing that a significant portion of the Dll4
expression in the growing tumour vessels requires ongoing VEGF
signalling. Thus, in tumours, VEGF can act to regulate the
expression of Dll4, as schematised in Figure 1A. Other ligands for
Notch, particularly Jagged1, have also recently been associated
with angiogenic endothelial cells (Sainson et al, 2008). It will be
very important to determine whether the different ligands provide
the same Notch signalling activity in angiogenic endothelial cells.
Dll4-Notch signalling affects expression of VEGF receptors
Separate studies have suggested that Notch signalling can alter
expression levels of all three VEGF receptors, schematised in
Figure 1B. The best-characterised case is that of VEGF-R2, which is
downregulated by either Notch or Hey1 (a Notch target gene).
Downregulation of VEGF-R2 has been observed following activa-
tion of Notch in cultured endothelial cells (Taylor et al, 2002).
Reciprocally, increased VEGF-R2 levels were observed in vessels of
Dll4 heterozygous mice or as a result of Dll4 blockade (Suchting
et al, 2007). This important finding suggests that Notch can
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VEGF-R2 axis. In cultured endothelial cells, downregulation of
VEGF-R2 may explain the reduced endothelial proliferation and
migration seen as a result of Notch signal activation (Taylor et al,
2002). In vivo, downregulation of VEGF-R2 has been proposed as a
mechanism to permit local differentiation of cells within a zone of
VEGF-driven angiogenesis: high levels of VEGF induce Dll4 in an
endothelial ‘tip cell’, which in turn provides a Notch signal and
decreased VEGF-R2 in downstream ‘stalk cells’ (Roca and Adams,
2007). Through this pathway of local cell differentiation, the tip
cells respond robustly to VEGF whereas the stalk cells respond in a
more muted manner.
Two recent reports suggest that VEGF-R1 expression may be
increased by Notch signalling. Reduced Notch activity, such as in
Dll4 heterozygous mice, resulted in reduced VEGF-R1 expression,
in addition to increased VEGF-R2 expression (Suchting et al,
2007). In addition, Dll4-Notch activity resulted in increased
expression of both the signalling form of VEFR-1 and the soluble
form of VEGF-R1 (sFlt1) in cultured endothelial cells (Harrington
et al, 2008). VEGF-R1 is a less potent signalling receptor than
VEGF-R2; thus it is not clear whether changing it’s coexpression
with VEGF-R2 would tend to increase, decrease or change the
character of the signal.
A recent study describes the VEGF-R3 gene as a direct
transcriptional target of the Notch signalling pathway, with NICD
and the CSL transcription factors binding directly to sites within
the human and murine VEGF-R3 promoters (Shawber et al, 2007).
In addition to showing a dramatic increase in VEGF-R3
expression, Shawber et al (2007) also showed an alteration of
endothelial VEGF responses as a result of Notch signal activation.
Notch signalling increased the cellular responses to VEGF-C,
presumably via upregulation of VEGF-R3, and decreased the
response to VEGF-A, via downregulation of VEGF-R2. An
analogous regulation of VEGF-R3 was also apparent in mouse
embryos following increased or decreased Notch activity. Finally,
although heterozygous Notch1 or VEGF-R1 mice are viable, doubly
heterozygous Notch1 /þVEGFR1 /þ embryos often die due to
vascular problems. The regulation of VEGF-R3 by Notch is likely
complex, as not all vascular beds showed increased VEGF-R3 levels
in response to Notch signalling. In zebrafish, Notch has been
proposed to downregulate the VEGF-R3 homologue, zFlt4, during
arterial specification and in the angiogenic tip cells of intersomitic
vessels (Siekmann and Lawson, 2007). Thus, Notch may interact
with the VEGF-R3 promoter in a context- and cell type-specific
fashion leading to different outcomes in promoter regulation. In
sum, these results suggest a complex interplay between Notch
activity and expression of VEGF receptors, resulting in changes in
how a particular endothelial cell will respond to VEGF signals.
Combination blockade of VEGF and Dll4 is more effective
in some tumours
An exciting opportunity has arisen because recent studies have
shown that blockade of Dll4 can have potent antitumour effects on
tumours that are resistant to VEGF inhibition (Noguera-Troise
et al, 2006; Ridgway et al, 2006). For example, the growth of a
sarcoma model that is very resistant to VEGF blockade was
strongly inhibited by blockade of Dll4-Notch (Noguera-Troise
et al, 2006). In addition, the tumour vessels in this model showed
dramatic disorganisation and dysfunction following Dll4-Notch
blockade. Furthermore, simultaneously blocking both VEGF and
Dll4 can have more potent effects in a variety of tumour models
than blockade of either factor alone (Ridgway et al, 2006; I
Noguera-Troise et al, unpublished results), including this sarcoma
model. Previous studies have shown that individual blockade of
VEGF and Dll4-Notch produces very different effects on the
morphology and function of tumour vessels (above, also Thurston
et al, 2007); however, to date, there is little information on the
effects of blocking both pathways in combination.
Although these observations raise the possibility of using
combination antiangiogenic therapies against the two pathways,
much remains to be learned regarding how to best exploit this
approach clinically. The factors produced by the tumour or
expressed within the tumour vessels that confer sensitivity to Dll4-
Notch blockade are unknown. To be fair, it must be said that the
corresponding factors that confer sensitivity to VEGF blockade are
also largely unknown, despite intense investigation for a decade. A
useful starting point may be to assume that high levels of Dll4-
Notch are in some way correlated with sensitivity to blockade.
Thus, further information from clinical specimens on the levels of
the various components of the VEGF and Delta-Notch pathways in
different tumour types will be very useful.
Mechanistically, the observation of potent combination effects is
difficult to fit into a simple model in which VEGF signalling
induces Dll4-Notch activity in the vasculature, which subsequently
helps to downregulate VEGF pathway activity in a neat feedback
loop. It is clear that although this model may be fundamentally
correct, other complexities are in play. For example, VEGF
signalling induces a number of different downstream pathways
and thus Dll4-Notch represents only one output. Conversely,
Dll4 is also apparently upregulated by pathways other than
VEGF, including in response to Notch signalling itself (Shawber
et al, 2003; Ridgway et al, 2006). An interesting approach might
be to consider whether Dll4 blockade is sensitising tumour vessels
to VEGF blockade or vice versa. Alternatively, the combined
blockade could be acting on separate subsets of tumour vessels
within a heterogeneous network. Future studies to document the
effect of combination blockade on the morphology and function of
tumour vessels, combined with studies of the interaction of the
pathways in cultured endothelial cells, are needed to shed further
light on this issue.
DISCUSSION AND FUTURE DIRECTIONS
The formation of a hierarchical network of vessels requires the
coordinated interplay of various signalling pathways. Even tumour
vessels, which are structurally abnormal and poorly functional, can
be rendered less efficient by interfering with vascular signalling
pathways. As described in this review, two important signalling
pathways with distinct roles in vascular development, namely the
VEGF and Delta-Notch pathways, interact at several levels to help
generate a hierarchical vessel network. Some of the interaction
appears to be at the level of gene transcription; for example, the
VEGF
Notch
Dll4
VEGF regulates Dll4-Notch
Notch
VEGFR-1 VEGFR-3 VEGFR-2
Regulation of expression levels
Regulation of activity
VEGFR-2
Notch regulates VEGF receptors
Figure 1 Schematic diagram summarising the different ways in which the
VEGF and Notch pathways interact. (A) VEGF stimulus, acting via VEGF-
R2, increases expression of Dll4 on endothelial cells, which in turn activates
Notch receptors on adjacent endothelial cells. (B) Activated Notch
receptors on endothelial cells can in turn positively (VEGF-R1, VEGF-R3) or
negatively (VEGF-R2) regulate the expression of VEGF receptors in those
cells.
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However, given the complexity of both the pathways, other levels
of cross-control are likely and need to be explored.
Conceptually, the VEGF system provides a driving signal from
surrounding tissues to endothelial cells (via cell-restricted VEGF
receptors) that calls for an increase in vascular function. However,
not all cells should respond equally to VEGF, and thus cell
fate decisions are essential for generating an efficient response.
Subsequently, the Delta-Notch pathway (particularly Dll4 and
Notch1) acts among the endothelial cells to respond appropriately
to the activating VEGF signal (Figure 2). In turn, an appropriate
vascular response will provide increased vascular function and
ultimately reduce the VEGF driving signal. Studies to date have
indicated at least two settings in the developing vasculature in
which VEGF drives a process and Delta-Notch helps to make cell
fate decisions within that process; in particular, the specification of
arterial cell fate and the specialisation of tip cells and stalk cells
within the growing front of angiogenic vessels. It will be important
to determine whether two different cell fate settings are applicable
to the very chaotic process of tumour angiogenesis.
Further studies are needed to examine the interaction of the
pathways in various tumour settings. We are just beginning to
explore how we can take combinatorial advantage of the VEGF
and Delta-Notch pathways for treating tumours, and a better
conceptual framework within the context of tumour angiogenesis
would help guide the experiments. Another issue will be to clarify
some of the disparate results on the regulation of VEGF receptors
by Delta-Notch activity: does VEGF receptor expression depend on
endothelial cell phenotype, on the nature of Notch signal or on the
presence of additional stimuli? Another important topic will be to
determine how some of the key downstream Notch target genes
(for example, ephrinB2) affect tumour vessels in the presence of
high VEGF levels. Another potentially fruitful approach will be to
examine whether other types of endothelial cell fate decisions in
development are guided by Delta-Notch. We are at an exciting time
for the convergence of basic vascular biology and tumour therapy.
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